ArticleRespiratory research2026
A USP15/KRT17-associated 13-gene prognostic cluster and functional validation in EGFR-mutant lung adenocarcinoma.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundEGFR-mutant lung adenocarcinoma (LUAD) exhibits significant prognostic heterogeneity despite the efficacy of tyrosine kinase inhibitors. To uncover the transcriptomic markers of rapid disease progression, we integrated clinical and transcriptomic data to develop robust prognostic biomarkers for risk stratification.
methodsWe utilized ensemble machine learning algorithms, including Random Survival Forest and XGBoost, to analyze transcriptomic data from 293 patients with EGFR-mutant LUAD. Single-cell transcriptomic analysis combined with copy number variation (CNV) profiling was employed to assess the cellular distribution and tumor epithelial contribution of the identified prognostic signature. The functional effects of the candidate biomarkers, USP15 and KRT17, and their dynamic regulation by oncogenic EGFR signaling were experimentally validated in EGFR-mutant cell lines using siRNA knockdown, pharmacological blockade (osimertinib), and gain-of-function assays.
resultsThe optimized XGBoost model identified a 13-gene cluster with strong predictive performance (C-index = 0.863), which was independently validated in an external cohort (log-rank P = 0.0117; 1-year AUC = 0.698). Single-cell transcriptomic analysis demonstrated that the detectable 11-gene subset exhibited a mixed tumor-microenvironment distribution, including expression within CNV-defined malignant epithelial cells. Functional experiments further demonstrated that USP15 and KRT17 promote tumor cell proliferation, clonogenic growth, and migration. Moreover, the expression of both genes was responsive to downstream EGFR signaling. Collectively, these findings establish a robust 13-gene prognostic gene cluster with a mixed cellular origin and identify USP15- and KRT17-associated biology as a promising direction for future mechanistic investigation in EGFR-mutant LUAD.
conclusionsWe identify a 13-gene prognostic cluster associated with poor survival in EGFR-mutant LUAD. These findings position the EGFR-regulated USP15/KRT17 axis as a novel framework for patient risk stratification, with potential implications for guiding targeted therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.